EFTX-G12V / EnFuego Therapeutics - LARVOL DELTA

Synergistic co-targeting of KRAS G12V and pan-TEAD by an EGFR-directed, inverted chimeric RNAi molecule (AACR 2026) - "Using this siRNA and EFTX-G12V we developed EFTX-G12V-pTEAD, that inhibits KRAS G12V, TEAD1-4 and downstream signaling at both the mRNA and the protein level. Using spatial profiling in the kidney, we found that our siRNA molecules do not enter podocytes and largely clear through the proximal tubules, therefore we anticipate the potential for less kidney toxicity and a wider therapeutic window using this therapeutic modality. Together our findings represent a technological advance in multi-oncogene targeting using RNAi and a therapeutic modality capable of addressing resistance to KRAS inhibitors."

Oncology • Pancreatic Cancer • Solid Tumor • EGFR • KRAS • TEAD1

Preclinical development of EFTX-G12V, a first-in-class EGFR-directed KRAS G12V selective inhibitor (AACR 2026) - "Lastly, we recently completed non-GLP safety studies in rat and mini-pig models and observed no test article related clinical observations, no injection site reactions and initial gross pathology detected no visible lesions across all tissues. Together these data indicate that EFTX-G12V has therapeutic efficacy in multiple cancer models, is delivered to tumor tissue with minimal somatic tissue exposure, and may be well tolerated."

Preclinical • Oncology • Pancreatic Cancer • Skin Cancer • Solid Tumor • EGFR • KRAS

A first-in-class EGFR-directed KRAS G12V selective inhibitor (AACR 2025) - "EFTX-G12V significantly inhibited tumor angiogenesis while pan-KRAS targeting had inconsistent effects suggesting that mutant-selective targeting has advantages within the tumor microenvironment. Together our findings represent a technologic advance in ligand-directed, mutant-selective oncogene targeting using RNAi and reveal new biologic insights in KRAS targeting that may have broader implications with regards to safety and efficacy."

Colon Cancer • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • EGFR • KRAS